In addition, the treated B220+/Mac1− cells were injected in immunodeficient mice, and the median time for leukemia onset in the animals was observed for daunorubicin, daunorubicin-loaded non-functionalized nanoparticles, and anti-B220 antibody-functionalized nanoparticles loaded with daunorubicin. Here, PTPRC is linked to leukemia.